Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Lancet. 2010 Dec 11;376(9757):2032-9. doi: 10.1016/S0140-6736(10)60962-2. Epub 2010 Dec 3.
Venous thrombosis is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, albeit at the cost of bleeding. Thus, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulation treatment. Many clinical and laboratory risk factors for recurrent venous thrombosis have been established. Nevertheless, prediction of recurrence in an individual patient remains a challenge. Detection of some laboratory markers is associated with only a moderate risk of recurrence, and the relevance of others is not known. Many patients have several risk factors and the effect of combined defects is obscure. Routine screening for these laboratory markers should therefore be abandoned. Risk assessment can be improved by measurement of global markers that encompass the effects of clotting and fibrinolytic disorders. Analysis of preliminary data suggests that risk assessment can also be refined through integration of prothrombotic coagulation changes and clinical risk factors.
静脉血栓栓塞是一种常见的疾病,经常复发。抗凝剂可以预防复发,但会增加出血的风险。因此,评估复发风险对于权衡抗凝治疗的风险和益处非常重要。许多临床和实验室的静脉血栓栓塞复发的危险因素已经确立。然而,预测个体患者的复发仍然是一个挑战。检测某些实验室标志物与中度复发风险相关,而其他标志物的相关性尚不清楚。许多患者有多种危险因素,联合缺陷的影响也不清楚。因此,应放弃这些实验室标志物的常规筛查。通过测量涵盖凝血和纤维蛋白溶解障碍影响的整体标志物,可以改善风险评估。初步数据分析表明,通过整合促血栓形成的凝血变化和临床危险因素,也可以细化风险评估。